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University, Taipei, Taiwan; and 6Institute of Population Health Science, National Health Research Institutes, Zhunan, TaiwanIntroduction: Diabetic kidney disease is an increasingly frequent cause of end-stage renal disease. How-
ever, mixed results were shown between glycated hemoglobin and mortality.
Methods: We used the average fasting plasma glucose (FPG) levels to predict mortality rates in long-term
hemodialysis patients. We enrolled 46,332 hemodialysis patients with diabetes mellitus, who were
registered in the Taiwan Renal Registry Data System between January 2005 and December 2012. The
patients were stratiﬁed based on the quartiles of average FPG levels measured for the ﬁrst (1-year FPG)
and third years (3-year FPG) of hemodialysis. Survival analysis was conducted via multivariable Cox
regression.
Results: After the ﬁrst year of hemodialysis, the mean FPG levels were 103.5  14.5, 144.7  11.5, 189.6 
15.2, and 280.8  1.2 mg/dl for the ﬁrst, second, third, and fourth quartile, respectively. The Kaplan-Meier
curve showed an incremental reduction in the survival as FPG levels increased (P < 0.0001). In the Cox
regression model, the adjusted hazard ratios were 1.15 (95% CI: 1.10–1.20), 1.30 (95% CI: 1.25–1.36), and
1.45 (95% CI: 1.39–1.51) for the pairwise comparisons between the ﬁrst quartile and the second, third, and
fourth quartile, respectively. Similar trends were observed by 3-year FPG. Patients whose FPG levels
increased had a 22% increased risk (95% CI: 1.16–1.29) for all-cause mortality compared with patients
whose FPG levels decreased.
Discussion: Our results suggest that the average FPG levels are useful predictors of all-cause mortality in
dialysis patients. In addition, an increasing trend in average FPG levels indicates poor survival.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T he incidence of diabetic kidney disease is rapidlyincreasing across the world.1 Furthermore, dia-
betic kidney disease accounts for nearly one-half of the
incident end-stage renal disease (ESRD) cases.2,3 Several
landmark trials such as the Diabetes Control and
Complication Trial4 with the Epidemiology of Diabetes
Interventions and Complications follow-up study,5 and
the United Kingdom Prospective Diabetes Study6 havespondence: Mai-Szu Wu and Yen-Chung Lin, Division of
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ved 9 June 2016; revised 19 August 2016; accepted 28
t 2016; published online 9 September 2016shown that sustained, long-term, intensive glycemic
control can reduce microvascular complications. How-
ever, numerous observational studies examining the
association between glycemic control and outcome in
dialysis patients have reported mixed conclusions. In a
cohort of 24,875 diabetic patients undergoing hemo-
dialysis at Fresenius Medical Care facilities, no associ-
ation between glycated hemoglobin (HbA1c) and
survival was observed during short-term follow-up;7
however, during a follow-up of 3 years, increased
risk of mortality was found for patients with HbA1c
levels of <48 mmol/mol or >97 mmol/mol (Interna-
tional Federation of Clinical Chemistry [IFCC] units).8
Similar results were reported in a larger cohort of
54,757 diabetic patients undergoing hemodialysis atKidney International Reports (2017) 2, 18–26
Y-C Lin et al.: Glucose Control in End-Stage Renal Disease CLINICAL RESEARCHDaVita facilities; speciﬁcally, HbA1c levels of <42
mmol/mol or >64 mmol/mol (IFCC units) were associ-
ated with an increased risk of mortality.9 At present,
clinical practice guidelines published by the Kidney
Disease Outcomes Quality Initiative and the Kidney
Disease: Improving Global Outcomes foundation
recommend that HbA1c levels be maintained over 53
mmol/mol (IFCC units) even in patients with advanced
chronic kidney disease and dialysis patients.10 In
Taiwan, blood tests are performed every month for
dialysis patients, and the reports are uploaded to the
Taiwan Renal Registry Data System (TWRDS) quar-
terly. However, multiple factors associated with ESRD
such as erythrocyte fragility and anemia may cause
divergent HbA1c levels. On the other hand, fasting
plasma glucose (FPG) levels are not affected by varia-
tions in hematocrit or uremic toxin levels. Hence, we
propose that short-term (1-year) or long-term (3-year)
FPG-based indicators may serve as predictors for
mortality rates in hemodialysis patients. In this study,
we used data recorded between 2005 and 2012 in the
TWRDS to determine whether glycemic levels can be
used to predict all-cause mortality in diabetic patients
undergoing maintenance hemodialysis.
RESEARCH DESIGN AND METHODS
This study was approved by the ethics committee of
Taipei Medical University’s institutional review board
(number: N201507028), and was conducted in accor-
dance with the principles of the Declaration of Hel-
sinki. The requirement for written informed consent
was waived, as the data analysis was blinded to the
patients’ identiﬁcation information.
The Taiwan Renal Registry Data System
The TWRDS was founded in 1987 for the accreditation
of dialysis therapy at medical facilities in Taiwan. To
receive reimbursements within the national health in-
surance plan, all dialysis units were asked to provide
the relevant laboratory data for the patients who un-
derwent dialysis at any of their facilities. In 1996, a
self-developed software program, HOPE, was used for
computerized data collection. Additional data were
gathered in 1997, and included information regarding
comorbidities such as hypertension, congestive heart
failure, left ventricular hypertrophy (deﬁned as a
chest-to-thoracic ratio of >0.5 on plain ﬁlm of the
chest), cerebral artery disease, and myocardial infarc-
tion; rehabilitation status; Kt/V as residual renal func-
tion plus hemodialysis dose; laboratory data with levels
of hematocrit, albumin, alkaline phosphatase, calcium
(Ca), phosphate (P), total cholesterol (TC), triglyceride
(TG), and intact parathyroid hormone; hepatitis sero-
logical results; and the use of medication for theKidney International Reports (2017) 2, 18–26management of hypertension and anemia.11 Therefore,
the data available in the TWRDS provide a robust
foundation for ongoing quality control of dialysis
practice at the national level.12–15
Patient Enrollment
At the end of 2012, a total of 569 hemodialysis units
were registered in Taiwan, which submitted seasonal
and annual reports to the TWRDS. A total of 115,565
patients were registered in the TWRDS between 2005
and 2012. Only those patients who had received he-
modialysis for more than 1 month were considered.
After excluding 4661 patients who had changed their
dialysis modality, the sample population consisted of
110,904 hemodialysis patients. Of these, 9232 patients
opted for peritoneal dialysis and 101,672 patients
(91.7%) opted for hemodialysis as their initial renal
replacement therapy modality. The following hemodi-
alysis patients were excluded from our study: 52,370
(51.5%) nondiabetic patients, 1972 (1.9%) patients
whose records did not include glucose level measure-
ments, and 998 (1%) patients who were either young
(<20 years) or extremely elderly (>90 years). There-
fore, a total of 46,332 (45.6%) patients with diabetes
mellitus were included in this study (Figure 1).
The data from the Union Clinical Laboratory were
reported to the TWRDS via the Internet by special
nurses at the participating dialysis units. The
biochemical data, including FPG levels, were collected
every 3 months. In the context of our study, the 1-year
average FPG levels (1-year FPG) represent the mean
levels of FPG in the ﬁrst year after the initiation of
hemodialysis, computed based on a maximum of 4
quarterly measurements. Similarly, the 3-year average
FPG levels (3-year FPG) represent the mean levels of
FPG in the ﬁrst 3 years after the initiation of hemodi-
alysis, computed based on a maximum of 12 quarterly
measurements. The patients were stratiﬁed based on
quartile limits of the distribution of 1- and 3-year FPG
values. Subsequently, the evolution of each patient was
evaluated as the change of status between the 1-year
average and the 3-year average with respect to the
patient’s assignment to a speciﬁc FPG quartile. After
this analysis, each patient was further assigned to
either the “decrease group” (when their corresponding
3-year FPG quartile was inferior to their 1-year quar-
tile) or the “increase group” (when their 3-year FPG
quartile was superior to their 1-year quartile).
The primary outcome measured in this study was the
3-year mortality rate in different quartiles of 1-year and
3-year FPG. Three-year mortality rate was also compared
between the FPG increase and decrease group. Patients
were identiﬁed as dead or lost to follow-up based on their
records of the national health insurance policy, which19
Figure 1. Flowchart of enrollment of the study cohort: from 1 January 2005 to 31 December 2012, a total of 46,332 patients with diabetes on
maintenance hemodialysis were identiﬁed from the Taiwan Renal Registry Data System (TWRDS). HD, hemodialysis; PD, peritoneal dialysis.
CLINICAL RESEARCH Y-C Lin et al.: Glucose Control in End-Stage Renal Diseaseprovides complete national coverage for all renal
replacement therapy expenditure in Taiwan.
Statistical Analysis
Descriptive statistics were expressed as mean  SD,
median (range), or frequency (percentage) for contin-
uous variables and proportions for categorical variables.
The 1-way analysis of variance test or the Kruskal-
Wallis test was used for the analysis of continuous
variables as appropriate, and the differences between
nominal variables were compared by the c2 test. The
log-rank test was used for the Kaplan-Meier analysis.
The level of signiﬁcance was set at 0.05, 2 tailed for all
tests. We performed a Cox regression analysis to esti-
mate the hazard ratios with 95% conﬁdence intervals
for mortality, stratiﬁed by quartiles of the distributions
of 1- and 3-year FPG values. Independent variables were
selected for multivariable analysis if they had a P
value < 0.05 in the univariable analysis and were also
clinically important confounders in the study. The case-
mix adjusted model included the following confound-
ing factors: age, sex, hypertension, congestive heart
failure, left ventricular hypertrophy, cerebral artery
disease, use of antihypertensive agents, laboratory data
(levels of hematocrit, albumin, alkaline phosphatase, Ca,
P, and intact parathyroid hormone), and Kt/V. All20descriptive and multivariable regression analyses were
performed using SPSS version 17.0 (SPSS Inc., Chicago,
IL) and SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
A total of 46,332 patients with diabetes mellitus un-
dergoing hemodialysis were included in this study.
Table 1 shows the demographic and clinical charac-
teristics of patients in the different groups deﬁned in
this study. The mean age of the patients was 63.2 
11.7 years, and 51% of the patients were male.
The average FPG levels were 103.5  14.5 (51.0–125.0)
mg/dl, 144.7  11.5 (125.3–165.0) mg/dl, 189.6  15.2
(165.1–217.8) mg/dl, and 280.8  61.2 (218.0–903.0)
mg/dl for the ﬁrst, second, third, and fourth quartile of
the distribution of 1-year FPG values, respectively.
With respect to the distribution of 3-year FPG values,
the average FPG levels were 107.6  14.6 (51.0–129.0)
mg/dl, 147.7  10.8 (129.1–166.7) mg/dl, 188.3  13.3
(166.7–213.0) mg/dl, and 268.1  54.4 (213.1–901.0)
mg/dl for the ﬁrst, second, third, and fourth quartile,
respectively. There was a slight predominance of male
patients in the groups deﬁned by the ﬁrst 3 quartiles of
the distribution of FPG values. The patients in all
quartiles exhibited similar incidence of comorbidities
(hypertension, congestive heart failure, left ventricularKidney International Reports (2017) 2, 18–26
Table 1. Baseline characteristics of 46,332 diabetic patients on maintenance hemodialysis by quartile of 1-yr FPG and 3-yr FPG in the TWRDS database, 2005–2012
Variable Total (N [ 46,332) First quartile (N [ 11,652) Second quartile (N [11,552) Third quartile (N [ 11,557) Fourth quartile (N [ 11,571) P
1-yr FPG (mg/dl, min–max) 103.5  14.5 (51.0–125.0) 144.7  11.5 (125.3–165.0) 189.6  15.2 (165.1–217.8) 280.8  61.2 (218.0–903.0)
Measurement times, median (interquartile) 4 (3, 4)
3-yr FPG (mg/dl, min–max) 107.6  14.6 (51.0–129.0) 147.7  10.8 (129.1–166.7) 188.3  13.3 (166.7–213.0) 268.1  54.4 (213.1–901.0)
Measurement times, median (interquartile) 6 (3, 10)
Age (yr) 63.2  11.7 62.9  12.1 63.5  11.8 63.5  11.4 62.9  11.3 <0.01
Male (%) 23,787 (51%) 6364 (55%) 6158 (53%) 5839 (51%) 5426 (47%) <0.0001
HTN (%) 23,313 (50%) 5979 (51%) 5870 (51%) 5792 (50%) 5672 (49%) 0.0033
CHF (%) 7447 (16%) 1832 (16%) 1820 (16%) 1861 (16%) 1934 (17%) 0.1410
LVH (%) 6516 (14%) 1694 (15%) 1638 (14%) 1602 (14%) 1582 (14%) 0.2450
CVA (%) 4779 (10%) 1133 (10%) 1214 (11%) 1205 (10%) 1227 (11%) 0.1080
CAD (%) 7658 (17%) 1871 (16%) 1904 (16%) 1954 (17%) 1929 (17%) 0.3523
MI (%) 1896 (4%) 466 (4%) 466 (4%) 489 (4%) 475 (4%) 0.8182
HTN drugs (%) 27,719 (60%) 6987 (60%) 7001 (61%) 6977 (60%) 6754 (58%) 0.0022
Laboratory data
TC (mg/dl) 171.4  38.3 169.6  36.5 168.7  37.3 171.9  38.4 175.3  40.7 <0.0001
TG (mg/dl) 181.2  116.2 152.4  92.8 170.3  105.0 189.2  115.7 213.0  138.0 <0.0001
Alb (g/dl) 3.7  0.4 3.8  0.4 3.7  0.4 3.7  0.4 3.7  0.4 <0.0001
Hct (%) 30.5  3.2 30.7  3.2 30.6  3.2 30.5  3.1 30.3  3.1 <0.0001
Ca (mg/dl) 9.1  0.7 9.1  0.7 9.1  0.7 9.1  0.7 9.0  0.7 <0.0001
P (mg/dl) 4.8  1.2 4.9  1.2 4.8  1.2 4.8  1.2 4.7  1.2 <0.0001
Alk-P (u/l) 119.0  92.8 111.7  88.7 113.4  84.9 119.1  91.8 131.9  103.4 <0.0001
i-PTH (pg/ml) 169.4  157.9 183.8  170.4 167.0  157.7 162.7  150.1 163.8  151.5 <0.0001
Ca*P 43.5  11.7 44.8  12.1 43.6  11.8 43.1  11.5 42.5  11.4 <0.0001
Kt/V 1.52  0.21 1.52  0.22 1.52  0.21 1.52  0.21 1.53  0.21 <0.0001
Alb, albumin; Alk-P, alkaline phosphatase; Ca, calcium; CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebral vascular accident; FPG, fasting plasma glucose; Hct, hematocrit; HTN, hypertension; i-PTH, intact parathyroid
hormone; LVH, left ventricular hypertrophy; MI, myocardial infarction; P, phosphorus; TC, total cholesterol; TG, triglyceride; TWRDS, Taiwan Renal Disease Registry System.
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CLINICAL RESEARCH Y-C Lin et al.: Glucose Control in End-Stage Renal Diseasehypertrophy, cerebral vascular accident, cerebral ar-
tery disease, and myocardial infarction) and use of
hypertensive drugs. However, there were signiﬁcant
differences with respect to TC and TG levels. Specif-
ically, with respect to the distribution of 1-year FPG
values, the TC and TG levels were increasing from the
ﬁrst to the fourth quartile. The same trend of TC and
TG was noted in quartiles of 3-year FPG values.
The 3-year mortality rates were 27.3%, 31.8%,
33.8%, and 38.5% for the ﬁrst, second, third, and
fourth quartile of the distribution of 1-year FPG values,
respectively. The slope of the Kaplan-Meier survival
curves based on the 1-year FPG values (Figure 2)
decreased by 16.5%, 23.7%, and 41.1% for the pair-
wise comparisons between the ﬁrst quartile and the
second, third, and fourth quartile (P < 0.0001),
respectively. Figure 3 shows a similar phenomenon for
the survival curves based on the 3-year FPG values
(3-year mortality rates: 26.7%, 31.3%, 33.0%, and
40.1% from the ﬁrst to the fourth quartile; slope
decreased by 17.2%, 23.6%, and 50.3% for compari-
sons between the ﬁrst quartile and the second, third,
and fourth quartile, respectively; P < 0.0001).
In the Cox regression analysis (Table 2), after adjust-
ing for age, gender, comorbidities (hypertension,
congestive heart failure, left ventricular hypertrophy,Figure 2. The Kaplan-Meier survival curves on the 1-year fasting plasma
38.5% in the ﬁrst, second, third, and fourth quartiles of 1-year average FPG
41.1% for the pairwise comparisons between the ﬁrst quartile and the s
quartile; Q2, second quartile; Q3, third quartile; and Q4, fourth quartile by
22cerebral vascular accident, cerebral artery disease, and
myocardial infarction), use of medication for hyperten-
sion, relevant laboratory results (albumin, hematocrit,
Ca, P, intact parathyroid hormone, and alkaline phos-
phatase), and Kt/V, the mortality hazard ratios were,
respectively, 1.15 (95% CI: 1.10–1.20), 1.30 (95% CI:
1.25–1.36), and 1.45 (95% CI: 1.39–1.51) for the second,
third, and fourth quartile compared with the ﬁrst
quartile of the distribution of 1-year FPG values. Simi-
larly, the mortality hazard ratios were 1.17 (95% CI:
1.12–1.22), 1.26 (95% CI: 1.21–1.311), and 1.57 (95% CI:
1.51–1.64)when comparing the second, third, and fourth
quartile with the ﬁrst quartile of 3-year FPG values.
After 3 years of hemodialysis, 32,424 (70%) patients
remained in the same quartile, whereas 13,908 patients
were assigned to a different quartile: 6745 patients (48%)
were thus included in the “increase group” and 7163
patients (52%) were included in the “decrease group.”
The adjusted hazard ratio of mortality was 1.22 (95% CI:
1.16–1.29, P < 0.01) in the “increase group” compared
with the “decrease group” (Table 3).
DISCUSSION
Our study showed that higher 1- and 3-year FPG
levels after hemodialysis are signiﬁcantly associated
with a higher mortality in the 3-year follow-up.glucose (FPG): 3-year mortality rates were 27.3%, 31.8%, 33.8%, and
(1-year FPG), respectively. Rates of reduction were 16.5%, 23.7%, and
econd, third, and fourth quartile, respectively (P < 0.0001). Q1, first
the distribution of 1-year FPG values.
Kidney International Reports (2017) 2, 18–26
Figure 3. The Kaplan-Meier survival curves on the 3-year fasting plasma glucose (FPG): 3-year mortality rates were 26.7%, 31.3%, 33.0%, and 40.1%
in the ﬁrst, second, third, and fourth quartiles of 3-year averge FPG (3-year FPG), respectively. Rates of reduction were 17.2%, 23.6%, and 50.3% for
the pairwise comparisons between the ﬁrst quartile and the second, third, and fourth quartile, respectively (P< 0.0001). Q1, first quartile; Q2, second
quartile; Q3, third quartile; and Q4, fourth quartile by the distribution of 3-year FPG values.
Y-C Lin et al.: Glucose Control in End-Stage Renal Disease CLINICAL RESEARCHFurthermore, an increase in FPG levels between the
ﬁrst and third year after the initiation of hemodialysis
was associated with a 22% increase in mortality. To the
best of our knowledge, this is the ﬁrst study that
demonstrated that higher average FPG levels indicate
increased mortality among diabetic patients receiving
hemodialysis. Thus, FPG levels may also be considered
as a useful surrogate marker in predicting mortality in
patients with diabetic uremia.Table 2. Crude and adjusted hazard ratio (HR) for all-cause mortality
of 46,332 diabetes patients on maintenance hemodialysis by quartile
of 1-yr FPG and 3-yr FPG in the Cox regression model
Groups of FPG Crude HR Adjusted HR
1-yr FPG
First quartile Reference Reference
Second quartile 1.21 (1.17–1.26)* 1.15 (1.10–1.20)*
Third quartile 1.34 (1.29–1.39)* 1.30 (1.25–1.36)*
Fourth quartile 1.55 (1.49–1.61)* 1.45 (1.39–1.51)*
3-yr FPG
First quartile Reference Reference
Second quartile 1.21 (1.16–1.26)* 1.17 (1.12–1.22)*
Third quartile 1.30 (1.25–1.35)* 1.26 (1.21–1.31)*
Fourth quartile 1.72 (1.66–1.79)* 1.57 (1.51–1.64)*
FPG, fasting plasma glucose.
*P < 0.01, adjusted for age, gender, hypertension, congestive heart failure, left ven-
tricular hypertrophy, cerebral vascular disease, coronary artery disease, myocardial
infarction, antihypertensive agents, albumin, hematocrit, calcium, phosphate, para-
thyroid hormone, alkaline phosphatase, and Kt/V.
Kidney International Reports (2017) 2, 18–26Diabetes mellitus is the major cause of ESRD in
Taiwan, accounting for one-half of the patients
receiving maintenance hemodialysis. In clinical prac-
tice, glycemic control is a difﬁcult task in this type of
population. HbA1c, which is formed by a nonenzy-
matic reaction between glucose and the hemoglobin in
red blood cells, reﬂects the concentration of glucose
over a 120-day period. HbA1c is the gold standard of
assessing glycemic control in the majority of diabetic
patients. However, previous studies showed inconsis-
tent results with respect to dialysis patients. This may
be attributed to the fact that, in dialysis patients, fac-
tors such as high blood pH, high levels of hemoglobin,
hemoglobinopathy, recent blood transfusion, use of
erythropoietin-stimulating agents, and recent bloodTable 3. Crude and adjusted hazard ratio (HR) for all-cause mortality
of diabetes patients on maintenance hemodialysis by trend of
fasting plasma glucose (FPG) in the Cox regression model
Trend of group Number Crude HR Adjust HR
13,908
Decrease FPG group 7163 Reference Reference
Increase FPG group 6745 1.22 (1.16–1.28)* 1.22 (1.16–1.29)*
*P < 0.01, adjusted for age, gender, hypertension, congestive heart failure, left ven-
tricular hypertrophy, cerebral vascular disease, coronary artery disease, myocardial
infarction, antihypertensive agents, albumin, hematocrit, calcium, phosphate, para-
thyroid hormone, alkaline phosphatase, and Kt/V.
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CLINICAL RESEARCH Y-C Lin et al.: Glucose Control in End-Stage Renal Diseaseloss can falsely decrease HbA1c. On the other hand,
uremic toxins such as elevated levels of blood urea
nitrogen and low blood pH will spuriously elevate
HbA1c levels.16 It was shown that mortality rates in
dialysis patients were higher for HbA1c levels below
42–53 mmol/mol, that is, estimated average glucose
levels of approximately 130–160 mg/dl. There are
several other tools for monitoring intermediate-term
glucose levels other than HbA1c. Fructosamine and
glycated albumin represent promising alternatives for
glycemic control assessment, as they provide surro-
gates of glycemic control during periods of 2 weeks.
Laboratory abnormalities and comorbidities associated
with the uremic state may still impact the accuracy of
these methods for assessing intermediate glycemic
control. Furthermore, the target ranges for fructos-
amine and glycated albumin levels are unknown in the
chronic kidney disease population, and such measure-
ments are not routinely available in clinical labora-
tories. Most important of all, there are limited data on
the relevance of such measurements.17,18 Chen et al.
demonstrated that, in patients with stage 3 and 4
chronic kidney disease, the average glucose levels
calculated based on HbA1c or fructosamine levels
may have underestimation compared with the mean
glucose levels measured using self-monitoring blood
glucose devices.19 In contrast, direct plasma glucose
measurements such as FPG represent the most reliable
assessment of glucose levels. FPG also has several ad-
vantages, such as follows: it is easy to measure and
shows less variability than postprandial glucose, which
is signiﬁcantly affected by different food intake.
In this study, higher 1- and 3-year FPG levels were
signiﬁcantly associated with higher mortality at 3 years
after the initiation of hemodialysis. These 2 FPG-based
indicators may have different clinical implications. In
the ﬁrst year of hemodialysis, the average FPG levels
reﬂect the initial degree of glycemic control achieved at
this stage of hemodialysis therapy. If a patient had
worse glycemic control when initiating hemodialysis,
he or she likely had a poorer survival outlook. The
possible explanations include disease complexity, us-
age of multiple drugs, unfavorable general condition,
or immunocompromised state during hyperglycemia at
the onset of hemodialysis. On the other hand, the 3-
year FPG levels reﬂect the long-term glycemic control
of hemodialysis therapy and the general condition of
the hemodialysis patient at this stage. In a Japanese
cohort of dialysis patients, poor glycemic control was
found to be a predictor of infection-related hospitali-
zation.20 In this case, higher glucose levels are likely
the result of multiple acute or chronic illnesses or
comorbidities that need further medical attention
during this period and can result in poor prognosis.24In dialysis patients, glucose control is often a matter
of debate, because clinical trials of glucose-lowering
agents do not include such patients. The Kidney Dis-
ease Outcomes Quality Initiative guideline advising to
maintain HbA1c levels between 53 and 75 mmol/mol
(IFCC units) is based on observational studies with
inconsistent conclusions. Data from a UK renal registry
suggested that higher HbA1c levels are associated with
increased mortality only in dialysis patients younger
than 60 years, but not in older patients.21 Glycemic
control data from Asian populations of dialysis patients
are scarce, and typically limited to a small study pop-
ulation.22,23 These data showed no association between
mean mortality rates and HbA1c levels after the initi-
ation of hemodialysis. However, for hemodialysis pa-
tients (n ¼ 245) with type 1 and type 2 diabetes
mellitus, the hazard ratio for mortality was higher in
patients with postprandial glucose levels > 180 mg/dl
than in those with levels < 160 mg/dl.22
In this study, patients whose FPG levels decreased
by the third year of hemodialysis had a more favorable
outcome than patients whose FPG levels increased. It is
interesting to note, however, that most patients (70%)
remained in the same group deﬁned by the quartiles of
the distribution of FPG levels, suggesting no signiﬁcant
evolution in any direction. A previous study showed
that lower HbA1c levels (<48 or <42 mmol/mol, IFCC
units) were associated with higher mortality in dialysis
patients.24 The term “burnt-out diabetes” refers to
spontaneous normalization of hyperglycemia in dialysis
patients, and is associated with hypoglycemia episodes.
The phenomenon can be a consequence of multiple
factors such as malnutrition, anemia, and impaired
excretion of oral antidiabetic drugs. This often leads to
down-titration or even cessation of diabetes treatment
in patients with ESRD, including insulin and oral
medication. However, when excluding anemia and
nutritional status, lower HbA1c levels seemed to be
associated with better survival in patients undergoing
maintenance dialysis.25 The results of our study also
showed that patients whose FPG levels decreased by
the third year of hemodialysis had better outcome than
those whose FPG levels increased, suggesting that,
despite the development of ESRD in diabetic patients,
glucose control still has a role in improving survival.
The cholesterol and TG values appeared to increase
progressively from the ﬁrst to the fourth quartile for
both the 1- and 3-year FPG distributions. However, the
correlation between cholesterol or TG levels and major
outcomes in hemodialysis patients are controversial. In
the guidelines published by the Kidney Disease:
Improving Global Outcomes foundation, the initiation
of statin is no longer suggested in dialysis patients.26
There are several reasons for this, the ﬁrst being theKidney International Reports (2017) 2, 18–26
Y-C Lin et al.: Glucose Control in End-Stage Renal Disease CLINICAL RESEARCHlack of solid evidence as to the beneﬁcial effect
regarding cardiovascular outcomes in dialysis pa-
tients.27,28 Second, as the concept of reverse epidemi-
ology suggests, lower cholesterol levels may be
associated with worse cardiovascular disease outcome,
independently or confounded by malnutrition or
inﬂammation when the patient undergoes maintenance
dialysis therapy.29,30 In this population, the role of
lipid levels is inconclusive. Therefore, we did not
adjust for the TC or TG levels in the Cox regression
model; instead, the adjusted factors included in our
Cox regression were those that are relevant to mortal-
ity, such as age, underlying disease, Ca/P, albumin
levels, and Kt/V.
There are some limitations in this study. First, the
speciﬁc cause of mortality such as infection or cardio-
vascular death is not available in this dataset. There-
fore, the speciﬁc effect of hyperglycemia on mortality
is hard to explore. Other residual confounding factors
included the lack of information about patients
receiving renal transplant and HbA1c level. However,
the number of patients with renal transplant is small,
that is, 200 subjects per year, which had a mild effect
on the cohort. Although HbA1c data were not assess-
able in the TWRDS, the accuracy of HbA1c in HD
population had not come to an agreement. The strength
of our study is that the data were collected based on a
long follow-up of a large study population, covering all
dialysis patients in Taiwan, with results from complete
and regular laboratory tests.
In conclusion, for the studied Taiwanese population
of diabetic patients undergoing hemodialysis, increased
mortality rates are associated with higher average FPG
levels at 1 and 3 years after the initiation of dialysis.
Patients whose FPG levels decrease between the ﬁrst
and the third year of hemodialysis have a more favor-
able outlook than patients whose FPG levels increase.
Further prospective, randomized trials are warranted to
conﬁrm our ﬁndings.
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